EirGen Pharma Product EIR-101 Passes Bioequivalence Study

EirGen Pharma are pleased to announce that Eir-101, a product which was developed as a treatment for metastatic breast cancer in postmenopausal women, has successfully passed its US Bioequivalence Study. This product will be filled with the US FDA in the coming months